Published in Annu Rev Med on January 01, 2008
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Whither or wither microbicides? Science (2008) 2.17
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
HIV-1 Nef: at the crossroads. Retrovirology (2008) 1.88
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One (2010) 1.88
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci U S A (2009) 1.77
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem (2009) 1.49
Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect (2008) 1.41
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A (2008) 1.26
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
The molecular basis of HIV entry. Cell Microbiol (2012) 1.19
A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One (2011) 1.19
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology (2010) 1.15
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother (2012) 1.14
Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology (2012) 1.12
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci U S A (2008) 1.10
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Compartmental transport model of microbicide delivery by an intravaginal ring. J Pharm Sci (2010) 1.09
Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol (2008) 1.09
The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol (2011) 1.07
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05
Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide. J Infect Dis (2011) 1.04
Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol (2011) 1.00
Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents (2010) 0.99
Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine (2008) 0.99
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci (2011) 0.98
Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology (2008) 0.97
Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophys J (2009) 0.97
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
Movements of HIV-virions in human cervical mucus. Biomacromolecules (2009) 0.95
Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol (2009) 0.95
Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptability. PLoS One (2010) 0.92
CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses (2010) 0.91
The Surprising Role of Amyloid Fibrils in HIV Infection. Biology (Basel) (2012) 0.91
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Antiviral Res (2010) 0.90
Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques. AIDS Res Hum Retroviruses (2010) 0.89
Update on animal models for HIV research. Eur J Immunol (2009) 0.89
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J (2012) 0.88
Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection. AIDS Res Hum Retroviruses (2009) 0.87
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One (2011) 0.87
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
Comparative evaluation of recombinant protein production in different biofactories: the green perspective. Biomed Res Int (2014) 0.86
Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother (2010) 0.85
PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrob Agents Chemother (2011) 0.85
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. J Gen Virol (2010) 0.84
A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J Biomed Biotechnol (2010) 0.84
World AIDS Day 2007: AIDS at 26, are we there yet? Retrovirology (2007) 0.83
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J Antimicrob Chemother (2013) 0.83
Convective diffusion of nanoparticles from the epithelial barrier toward regional lymph nodes. Adv Colloid Interface Sci (2013) 0.83
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One (2013) 0.82
RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther (2009) 0.81
The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr Purif (2009) 0.81
Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection. J Acquir Immune Defic Syndr (2011) 0.80
Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J Virol (2008) 0.80
Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. J Infect Dis (2013) 0.80
Carbohydrate recognition by the antiviral lectin cyanovirin-N. J Am Chem Soc (2012) 0.79
Natural anti-CCR5 antibodies in HIV-infection and -exposure. J Transl Med (2011) 0.79
Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrob Agents Chemother (2012) 0.78
A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris. Protein Expr Purif (2015) 0.77
The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential. Antimicrob Agents Chemother (2009) 0.77
Inhibition of HIV-1 infection in ex vivo cervical tissue model of human vagina by palmitic acid; implications for a microbicide development. PLoS One (2011) 0.77
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep (2017) 0.77
Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion. Biophys J (2015) 0.77
CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge. Sci Rep (2016) 0.76
HIV/AIDS therapy and prevention: The two solitudes. Can J Infect Dis Med Microbiol (2009) 0.75
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge. Antimicrob Agents Chemother (2015) 0.75
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Online submission makes authors do all the work. Nature (2005) 3.21
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol (2006) 3.13
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Whither or wither microbicides? Science (2008) 2.17
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol (2006) 2.12
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr (2005) 1.99
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology (2004) 1.72
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2005) 1.68
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59
Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med (2006) 1.56
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol (2005) 1.54
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol (2013) 1.54
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A (2009) 1.53
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (2014) 1.53
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol (2005) 1.42
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem (2012) 1.42
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology (2005) 1.40
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol (2013) 1.38
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine (2009) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 1.34
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol (2003) 1.29
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog (2009) 1.29
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology (2004) 1.23
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry (2009) 1.20
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif (2006) 1.19
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses (2010) 1.18
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood (2003) 1.18
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother (2012) 1.14
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry (2007) 1.13
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Programming desiccation-tolerance: from plants to seeds to resurrection plants. Curr Opin Plant Biol (2011) 1.12
Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology (2009) 1.11
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses (2003) 1.10
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci U S A (2008) 1.10
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses (2006) 1.09
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology (2009) 1.08
MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog (2012) 1.07
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol (2011) 1.07
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol (2003) 1.06
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology (2006) 1.06
Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses (2006) 1.06
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release (2011) 1.05
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology (2007) 1.04
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology (2008) 1.04
A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. J Virol (2002) 1.03
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A (2012) 1.03